Recent Press Releases

Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis

INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the inves

Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015

Diverse pipeline compounds target key cancer pathways

INDIANAPOLIS, April 20, 2015 /PRNewswire/ --&n

Early Findings with Pembrolizumab, Merck's Investigational Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

Pembrolizumab Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer

Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman

Biogen CEO George A. Scangos and Johnson & Johnson Worldwide Chairman for Pharmaceuticals Joaquin Duato Assume New Posts ; Castellani Announces Retirement Washington, D.C. (April 16, 2015)...

PFIZER WINS JURY VERDICT IN FIRST ZOLOFT CASE TO GO TO TRIAL

NEW YORK (April 17, 2015) – Pfizer today released the following statement regarding the jury verdict in favor of the Company in the Pesante case, the first case to go to trial in Trace Foster...

Mylan Comments on Recent Media Speculation

POTTERS BAR, England, April 17, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today commented on recent media speculation. Mylan Executive Chairman Robert J. Coury commented, "We note that there...

Actavis Announces FDA Approval of Expanded Label for BOTOX(R) (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

Label updates include addition of two thumb flexor muscles and increased maximum cumulative dose DUBLIN, April 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), which recently completed the...

"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC

GENEVA, April 17, 2015 /PRNewswire/ --

CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

Opdivo Demonstrates Superior Overall Survival Compared to Docetaxel in Patients with Previously-Treated Non-Squamous Non-Small Cell Lung Cancer Friday, April 17, 2015 RINCETON, N.J.--Bristol-Myers...

Annual General Meeting Approves Dividend Increase

Executive Board actions approved by a significant majority Darmstadt, Germany, April 17, 2015 – At the Annual General Meeting of Merck held in Frankfurt am Main today, shareholders approved...

Merck Proposes Dividend Increase to AGM After a Year of Key Strategic Moves – Foundation Set for Further Organic Growth

Major highlights of 2014 include offer for Sigma-Aldrich, alliance with Pfizer and integration of AZ Electronic Materials  Merck proposes a dividend increase of € 0.05 to € 1.00 Darmstadt,...

Amgen Announces Webcast Of 2015 First Quarter Financial Results

THOUSAND OAKS, Calif., April 16, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will

Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full...

ABBVIE'S INVESTIGATIONAL CHRONIC HEPATITIS C TREATMENT GRANTED PRIORITY REVIEW IN JAPAN

- ABBVIE'S INVESTIGATIONAL, INTERFERON AND RIBAVIRIN-FREE TREATMENT IN JAPAN CONSISTS OF A 12-WEEK, TWO DIRECT-ACTING ANTIVIRAL, FIXED-DOSED COMBINATION OF PARITAPREVIR/RITONAVIR WITH OMBITASVIR,...

VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents

MOUNTAIN VIEW, CA--(Marketwired - April 15, 2015) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs...

Pacira Receives Subpoena from the U.S. Department of Justice

PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 16, 2015-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office...

FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure

Corlanor is the First New Chronic Heart Failure Medicine Approved by the FDA in Nearly a Decade

THOUSAND OAKS, Calif.,